These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26683239)

  • 61. B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review.
    Dangour AD; Whitehouse PJ; Rafferty K; Mitchell SA; Smith L; Hawkesworth S; Vellas B
    J Alzheimers Dis; 2010; 22(1):205-24. PubMed ID: 20847412
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cardiac risk factors and potential treatments in Alzheimer's disease.
    Bergmann C; Sano M
    Neurol Res; 2006 Sep; 28(6):595-604. PubMed ID: 16945210
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease? Part II: Management, prevention and future perspective.
    Davey DA
    Neurodegener Dis Manag; 2014; 4(3):261-70. PubMed ID: 25095820
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study.
    Sen A; Akinola M; Tai XY; Symmonds M; Davis Jones G; Mura S; Galloway J; Hallam A; Chan JYC; Koychev I; Butler C; Geddes J; Van Der Putt R; Thompson S; Manohar SG; Frangou E; Love S; McShane R; Husain M
    Trials; 2021 Jul; 22(1):508. PubMed ID: 34332638
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of epilepsy for people with Alzheimer's disease.
    Liu J; Wang LN
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011922. PubMed ID: 33973646
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevention of Alzheimer's disease and dementia. Major findings from the Kungsholmen Project.
    Fratiglioni L; Winblad B; von Strauss E
    Physiol Behav; 2007 Sep; 92(1-2):98-104. PubMed ID: 17588621
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.
    Frisoni GB; Molinuevo JL; Altomare D; Carrera E; Barkhof F; Berkhof J; Delrieu J; Dubois B; Kivipelto M; Nordberg A; Schott JM; van der Flier WM; Vellas B; Jessen F; Scheltens P; Ritchie C
    Alzheimers Dement; 2020 Oct; 16(10):1457-1468. PubMed ID: 32815289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ethical and social implications of using predictive modeling for Alzheimer's disease prevention: a systematic literature review protocol.
    Angehrn Z; Nordon C; Turner A; Gove D; Karcher H; Keenan A; Neumann M; Sostar J; de Reydet de Vulpillieres F
    BMJ Open; 2019 Mar; 9(3):e026468. PubMed ID: 30833325
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nimodipine for primary degenerative, mixed and vascular dementia.
    López-Arrieta ; Birks J
    Cochrane Database Syst Rev; 2001; (1):CD000147. PubMed ID: 11279679
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia.
    McGuinness B; Todd S; Passmore P; Bullock R
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004034. PubMed ID: 19821318
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders.
    Zupanic E; Kramberger MG; von Euler M; Norrving B; Winblad B; Secnik J; Fastbom J; Eriksdotter M; Garcia-Ptacek S
    J Alzheimers Dis; 2020; 73(3):1013-1021. PubMed ID: 31884483
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical
    Tariot PN; Lopera F; Langbaum JB; Thomas RG; Hendrix S; Schneider LS; Rios-Romenets S; Giraldo M; Acosta N; Tobon C; Ramos C; Espinosa A; Cho W; Ward M; Clayton D; Friesenhahn M; Mackey H; Honigberg L; Sanabria Bohorquez S; Chen K; Walsh T; Langlois C; Reiman EM;
    Alzheimers Dement (N Y); 2018; 4():150-160. PubMed ID: 29955659
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
    Meinert CL; Breitner JC
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S7-S14. PubMed ID: 18632005
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Contributions of a risk assessment approach to the prevention of Alzheimer's disease and dementia.
    Anstey KJ; Eramudugolla R; Dixon RA
    J Alzheimers Dis; 2014; 42 Suppl 4():S463-73. PubMed ID: 25114084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.